Evaluation of the effect of D-002, a mixture of beeswax alcohols, on osteoarthritis symptoms
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Nonsteroidal anti-inflammatory drugs relieve osteoarthritis(OA) symptoms but cause adverse effects. D-002, a mixture of beeswax alcohols,is effective against experimental OA. A pilot study found that D-002 (50 mg/day)for 8 weeks improves OA symptoms. The aim of this study was to investigate theeffects of D-002 (50 to 100 mg/day) administered for 6 weeks on OA symptoms. Methods: Patients with OA symptoms were double-blindly randomized to D-002(50 mg) or placebo for 6 weeks. Symptoms were assessed by the Western Ontarioand McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogscale (VAS) scores. Patients without symptom improvement at week 3 were titratedto two daily tablets. The primary outcome was the total WOMAC score. WOMACpain, joint stiffness and physical function scores, VAS score, and use of rescuemedications were secondary outcomes. Results: All randomized patients (n = 60) completed the study, and 23 experienceddose titration (two in the D-002 and 21 in the placebo groups). At study completion,D-002 reduced total WOMAC (65.4%), pain (54.9%), joint stiffness (76.8%), andphysical function (66.9%) WOMAC scores, and the VAS score (46.8%) versusplacebo. These reductions were significant beginning in the second week, andbecame enhanced during the trial. The use of rescue medication by the D-002(6/30) group was lower than that in the placebo (17/30) group. The treatment waswell tolerated. Seven patients (two in the D-002 and five in the placebo group)reported adverse events. Conclusions: These results indicate that D-002 (50 to 100 mg/day) for 6 weeksameliorated arthritic symptoms and was well tolerated.
Abstract
Background/Aims: Nonsteroidal anti-inflammatory drugs relieve osteoarthritis(OA) symptoms but cause adverse effects. D-002, a mixture of beeswax alcohols,is effective against experimental OA. A pilot study found that D-002 (50 mg/day)for 8 weeks improves OA symptoms. The aim of this study was to investigate theeffects of D-002 (50 to 100 mg/day) administered for 6 weeks on OA symptoms. Methods: Patients with OA symptoms were double-blindly randomized to D-002(50 mg) or placebo for 6 weeks. Symptoms were assessed by the Western Ontarioand McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogscale (VAS) scores. Patients without symptom improvement at week 3 were titratedto two daily tablets. The primary outcome was the total WOMAC score. WOMACpain, joint stiffness and physical function scores, VAS score, and use of rescuemedications were secondary outcomes. Results: All randomized patients (n = 60) completed the study, and 23 experienceddose titration (two in the D-002 and 21 in the placebo groups). At study completion,D-002 reduced total WOMAC (65.4%), pain (54.9%), joint stiffness (76.8%), andphysical function (66.9%) WOMAC scores, and the VAS score (46.8%) versusplacebo. These reductions were significant beginning in the second week, andbecame enhanced during the trial. The use of rescue medication by the D-002(6/30) group was lower than that in the placebo (17/30) group. The treatment waswell tolerated. Seven patients (two in the D-002 and five in the placebo group)reported adverse events. Conclusions: These results indicate that D-002 (50 to 100 mg/day) for 6 weeksameliorated arthritic symptoms and was well tolerated.
참고문헌 (46)
- Lozada C, "Osteoarthritis", Med Rheumatol, 15, pp.12~23 (2010)
- Iagnocco A, "Osteoarthritis: research update and clinical applications", Rheumatology (Oxford), 51(Suppl 7), pp.vii2~vii5 (2012)
- Litwic A, "Epidemiology and burden of osteoarthritis", Br Med Bull, 105, pp.185~199 (2013)
- Lee YC, "The benefit of nonpharmacologic therapy to treat symptomatic osteoarthritis", Curr Rheumatol Rep, 10, pp.5~10 (2008)
- Bannwarth B., "Acetaminophen or NSAIDs for the treatment of osteoarthritis", Best Pract Res Clin Rheumatol, 20, pp.117~129 (2006)
- Zhang W, "OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence", Osteoarthritis Cartilage, 15, pp.981~1000 (2007)
- Moore RA, "Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inf lammatory drugs: balancing gastrointestinal and cardiovascular risk", BMC Musculoskelet Disord, 8, pp.73~ (2007)
- Cherubino P, "The management of chronic pain in important patient subgroups", Clin Drug Investig, 32(Suppl 1), pp.35~44 (2012)
- McCarberg B, "Complexities in the pharmacologic management of osteoarthritis pain", Curr Med Res Opin, 29, pp.539~548 (2013)
- Merashly M, "Management of knee osteoarthritis:an evidence-based review of treatment options", J Med Liban, 60, pp.237~242 (2012)
- Mas R, "D-002: antiulcer, antioxidant, antiinflammatory", Drugs Future, 26, pp.731~744 (2001)
- Leone S, "Dual acting anti-inflammatory drugs", Curr Top Med Chem, 7, pp.265~275 (2007)
- Carbajal D, "Anti-inflammatory activity of D-002: an active product isolated from beeswax", Prostaglandins Leukot Essent Fatty Acids, 59, pp.235~238 (1998)
- Ravelo Y, "Evaluation of anti-inf lammatory and antinociceptive effects of D-002(beeswax alcohols)", J Nat Med, 65, pp.330~335 (2011)
- Mendoza S, "Ameliorating effects of D-002, a mixture of beeswax alcohols, on monosodium iodoacetate-induced osteoarthritis in rats", Int J Pharm Sci Rev Res, 19, pp.10~15 (2013)
- Rodriguez I, "Effects of D-002, a mixture of beeswax alcohols, on osteoarthritis symptoms:a randomized placebo-controlled study", IOSR J Pharm, 2, pp.1~9 (2012)
- Altman R, "Development of criteria for the classification and reporting of osteoarthritis:classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association", Arthritis Rheum, 29, pp.1039~1049 (1986)
- Altman R, "The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip", Arthritis Rheum, 34, pp.505~514 (1991)
- Batlle-Gualda E, "Adaptacion transcultural del cuestionario WOMAC especifico para artrosis de rodilla y cadera", Rev Esp Reumatol, 26, pp.38~45 (1999)
- Angst T, "Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required simple sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities", Arthritis Rheum, 45, pp.384~391 (2001)
- Jinks C, "Measuring the population impact of knee pain and disability with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)", Pain, 100, pp.55~64 (2002)
- Salaffi F, "Reliability and validity of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index in Italian patients with osteoarthritis of the knee", Osteoarthritis Cartilage, 11, pp.551~560 (2003)
- Gonzalez VL, "Nuevo metodo por Cromatografia Gaseosa Capilar para el analisis del ingrediente activo D002", Rev CENIC Cienc Quim, 39, pp.123~124 (2008)
- Gruenwald J, "Effect of glucosamine sulfate with or without omega-3 fatty acids in patients with osteoarthritis", Adv Ther, 26, pp.858~871 (2009)
- Goregaonkar A, "Comparative assessment of the effectiveness and tolerability of lornoxicam 8 mg BID and diclofenac 50 mg TID in adult indian patients with osteoarthritis of the hip or knee: a 4-week, double-blind, randomized, comparative, multicenter study", Curr Ther Res, 70, pp.56~68 (2009)
- Naranjo CA, "A method for estimating the probability of adverse drug reactions", Clin Pharmacol Ther, 30, pp.239~245 (1981)
- Lequesne MG, "Indexes of severity for osteoarthritis of the hip and knee. Validation:value in comparison with other assessment tests", Scand J Rheumatol Suppl, 65, pp.85~89 (1987)
- Lequesne M, "Indices of severity and disease activity for osteoarthritis", Semin Arthritis Rheum, 20(6 Suppl 2), pp.48~54 (1991)
- Lequesne MG, "The algofunctional indices for hip and knee osteoarthritis", J Rheumatol, 24, pp.779~781 (1997)
- Srikanth VK, "A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis", Osteoarthritis Cartilage, 13, pp.769~781 (2005)
- Rizzoli R, "Vitamin D supplementation in elderly or postmenopausal women:a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)", Curr Med Res Opin, 29, pp.305~313 (2013)
- "Direction of Medical Register and Health Statistics, Health Annual Report 2010" (2010)[URL]
- Singh G, "Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey", Am J Manag Care, 8(15 Suppl), pp.S383~S391 (2002)
- Zhang W, "The placebo effect and its determinants in osteoarthritis:meta-analysis of randomised controlled trials", Ann Rheum Dis, 67, pp.1716~1723 (2008)
- Clegg DO, "Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis", N Engl J Med, 354, pp.795~808 (2006)
- Selvan T, "A clinical study on glucosamine sulfate versus combination of glucosamine sulfate and NSAIDs in mild to moderate knee osteoarthritis", ScientificWorldJournal, 2012, pp.902676~ (2012)
- Schneider H, "Symptom-modifying effect of chondroitin sulfate in knee osteoarthritis:a meta-analysis of randomized placebo-controlled trials performed with structum(®)", Open Rheumatol J, 6, pp.183~189 (2012)
- Carbajal D, "Anti-ulcer activity of higher primary alcohols of beeswax", J Pharm Pharmacol, 47, pp.731~733 (1995)
- Carbajal D, "Possible cytoprotective mechanism in rats of D-002, an anti-ulcerogenic product isolated from beeswax", J Pharm Pharmacol, 48, pp.858~860 (1996)
- Carbajal D, "Effect of D-002 on gastric mucus composition in ethanol-induced ulcer", Pharmacol Res, 42, pp.329~332 (2000)
- Molina V, "Antioxidant effect of D-002 on gastric mucosa of rats with experimentally induced injury", J Med Food, 4, pp.79~83 (2001)
- Perez Y, "Protective effect of D-002, a mixture of beeswax alcohols, against indomethacin-induced gastric ulcers and mechanism of action", J Nat Med, 67, pp.182~189 (2013)
- Menendez R, "Inhibition of rat microsomal lipid peroxidation by the oral administration of D002", Braz J Med Biol Res, 33, pp.85~90 (2000)
- Menendez R, "Effects of D-002on lipid peroxidation in older subjects", J Med Food, 4, pp.71~77 (2001)
- Lopez E, "Effects of D-002 (beeswax alcohols) on lipid peroxidation in middle-aged and older subjects", Lat Am J Pharm, 27, pp.695~703 (2008)
- Rodriguez I, "Comparison of the antioxidant effects of D-002 (beeswax alcohols) and grape seed extract (GSE) on plasma oxidative variables in healthy subjects", Lat Am J Pharm, 29, pp.255~262 (2010)